About this journal
Aims and scope
Expert Review of Molecular Diagnostics [ISSN 1473-7159]; [e-ISSN 1744-8352] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers in molecular diagnostics. The journal covers the detection and monitoring of the molecular causes of disease that are being translated into ground-breaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting.
Expert Review of Molecular Diagnostics provides a forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.
Articles focus on the following key areas:
- Contemporary genetic and genomic technologies including deep sequencing and genome-wide association studies.
- Molecular tools for infectious disease testing and detection of multiple resistant bacteria.
- Latest discoveries in oncology diagnostics.
- Progress in non-invasive prenatal testing, including molecular markers and ethical considerations.
- 'Omic’ diagnostic technologies including: pharmacogenomic, epigenomic, proteomic and metabolomic technologies.
- Disease predisposition and inherited genetic diseases testing.
- Diagnostic tests for point-of-care settings and for resource-limited settings as well as progress in developing handheld devices for molecular diagnostic tests.
- Progress in developing handheld devices for molecular diagnostic tests.
- Biomarker development and usage to target patient groups for personalized medicine.
- Tools for molecular prognosis.
- Novel technologies and developments in molecular diagnostic techniques.
- Regulatory, ethical and payor perspectives in molecular diagnostics.
Each issue of Expert Review of Molecular Diagnostics contains:
- Reviews on current and emerging topics relating to molecular diagnostics.
- Editorials discussing contentious issues in the field.
- Diagnostic profiles featuring independent, expert evaluations of diagnostic tests.
- Original Research - manuscripts detailing clinical studies with a presentation of previously unpublished data.
Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;
Article Highlights – an executive summary of the author’s most critical points.
Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.
Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Review of Molecular Diagnostics, part of the Expert Collection brand.
Authors can publish gold open access in this journal and may choose to publish using our Accelerated Publication services.
For any pre-submission enquiries, please contact the Commissioning Editor.
Journal metrics
Usage
- 228K annual downloads/views
Citation metrics
- 3.9 (2023) Impact Factor
- Q1 Impact Factor Best Quartile
- 4.8 (2023) 5 year IF
- 6.6 (2023) CiteScore (Scopus)
- Q1 CiteScore Best Quartile
- 0.770 (2023) SNIP
- 0.823 (2023) SJR
Speed/acceptance
- 7 days avg. from submission to first decision
- 70 days avg. from submission to first post-review decision
- 10 days avg. from acceptance to online publication
- 38% acceptance rate
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Editor-in-Chief
Prof. Attila T Lorincz, Queen Mary University of London, London, UK
Associate Editors
Dr. William C S Cho, Queen Elizabeth Hospital, Yau Ma Tei, Hong Kong
Prof. Samir Hanash, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Prof. George Poste, Arizona State University, Tempe, AZ, USA
Prof. Jeffrey S Ross, Albany Medical College, Albany, NY, USA
Editorial Board Members
Prof. Pascal Borry, Katholieke Universiteit Leuven, Leuven, Belgium
Prof. George Calin, University of Texas: MD Anderson Cancer Center, Houston, TX, USA
Prof. Allen Chan, The Chinese University of Hong Kong, Hong Kong SAR, China
Prof. Liang Cheng, Brown University, Providence, RI, USA
Dr. Alessia Cimadamore, Polytechnic University of the Marche Region, Ancona, Italy
Prof. Ajay Goel, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
Prof. Gary Hardiman, Queen's University Belfast, Belfast, UK
Dr. Jan Trøst Jørgensen, Dx-Rx Institute, Fredensborg, Denmark
Prof. Allan Klein, Cleveland Clinic, Cleveland, OH, USA
Prof. Gerald Kost, UC Davis, Sacremento, CA, USA
Prof. Lance Liotta, George Mason University, Fairfax County, VA, USA
Prof. Dennis Lo, The Chinese University of Hong Kong, Hong Kong, China
Prof. Matthew William McCarthy, Cornell University, Tompkins County, NY, USA
Prof. Joy Sarojini Michael, Christian Medical College, Vellore, India
Prof. Rodolfo Montironi, Polytechnic University of the Marche Region, Ancona, Italy
Prof. Shuji Ogino, Dana-Farber Cancer Institute, Boston, MA, USA
Prof. Stephen Povoski, Ohio State University, Columbus, OH, USA
Dr. Ken Pritzker, RNA Diagnostics Inc., Toronto, ON, Canada
Prof. Jean-Marc Rolain, Aix-Marseille Université, Marseille, France
Prof. Manuel Salto-Tellez, Queen’s University Belfast, Belfast, UK
Prof. Oliver Schildgen, Hospital of the Private University, Cologne, Germany
Prof. Jens Schittenhelm, Eberhard Karls University Tuebingen, Tuebingen, Germany
Prof. Jan Traeger-Synodinos, National and Kapodistrian University of Athens, Athens, Greece
Prof. Barbara Van Der Pol, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
Prof. Tomasz Wojdacz, University of Aarhus, Aarhus, Denmark
Abstracting and indexing
Expert Review of Molecular Diagnostics
is included in the following abstracting and indexing services:Biobase; Biotechnology Citation Index™; Chemical Abstracts; Current Contents®/Clinical Medicine; EMBASE/Excerpta Medica; Index to Scientific Reviews®; Journal Citation Reports/Science Edition®; MEDLINE/Index Medicus
Science Citation Index Expanded™ (SciSearch®); Scopus.
Ranking: 17/77 Pathology
Open access
Expert Review of Molecular Diagnostics is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
Use our APC finder to calculate your article publishing charge
News, offers and calls for papers
News and offers
- Discuss your submission with Commissioning Editor Edward Spofford: [email protected]
12 issues per year
Associated with:
- Expert Review of Proteomics (2004 - current)
- Expert Review of Neurotherapeutics (2001 - current)
- Expert Review of Precision Medicine and Drug Development: Personalized medicine in drug development and clinical practice (null - current)
Advertising information
Would you like to advertise in Expert Review of Molecular Diagnostics?
Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in Expert Review of Molecular Diagnostics.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors